MCK·McKesson Corporation
MCK|Earnings Snapshot
EPS
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'27 | $10.77 | - | - |
| Q1'27 | $9.63 | $9.93 | +3.1% |
| Q4'26 | $11.68 | $11.69 | +0.1% |
| Q3'25 | $9.05 | $9.86 | +8.9% |
| Q2'25 | $8.15 | $8.26 | +1.4% |
| Q1'25 | $9.83 | $10.12 | +3.0% |
Revenue
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q2'27 | $111.0B | - | - |
| Q1'27 | $104.8B | $105.4B | +0.6% |
| Q4'26 | $102.4B | $96.3B | -5.9% |
| Q3'25 | - | $103.2B | - |
| Q2'25 | - | $97.8B | - |
| Q1'25 | - | $90.8B | - |
Market Data
MCK Stock Snapshot
MCK is currently trading at $860.28, giving McKesson Corporation a market cap of 100.54B and a P/E ratio of 21.9. Today's range spans $869.36–$905.66, with shares opening at $871.40 and moving up $0.00 (0.0%) from the prior close. DailyIQ's technical score sits at 64/100 (HOLD) with a news sentiment reading of 67/100.
Over the past year MCK has traded between $673.38 and $999.00 - the current price is +27.8% off the 52-week low and -13.9% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $986.94 (range $845.00–$1080.00), implying upside of +14.7%.
MCK trades at $860.28 (in the middle of its 52-week range within $673.38–$999.00) - and the HOLD signal (64/100) reflects a market that's fairly priced relative to near-term expectations rather than one that's mispriced in either direction. (P/E: 21.9) At 100.54B in Healthcare market cap, bullish sentiment (67/100) confirms the lack of near-term narrative catalyst. The thesis is intact; the timing is patient.
In neutral phases, large-cap Healthcare names like MCK are often where sector rotation debates play out quietly, at 100.54B in capitalization, the stock receives incremental allocation from funds reducing mega-cap exposure without the volatility of a small-cap entry. The 64/100 (HOLD) and bullish sentiment (67/100) at $860.28 (in the middle of its 52-week range) describe a stock that is being considered rather than avoided.
Company Insights: McKesson (MCK)
McKesson’s most recent Q1 2027 results show an 8 % revenue rise to $105.38 B and a 20 % EPS jump to $9.93, outpacing estimates. The company also completed a substantial portion of its long‑running share‑repurchase program, reinforcing management confidence in cash flow. Adjusted earnings guidance was raised, signaling optimism about future profitability. Despite a slight dip in Q4 2026 revenue, EPS beat expectations in every quarter of the last year, underscoring earnings resilience. The company’s diversified segments, pharmaceutical distribution, technology solutions, and medical‑surgical supplies, provide multiple revenue streams that cushion against sector volatility.
At a forward P/E of 22.1x, McKesson trades well below the peer average of 53x, indicating a valuation cushion relative to the broader medical‑distribution sector. The current price of $869.58 sits 18.1 % below its 52‑week high of $999, offering a margin of safety for investors seeking entry points. Analyst consensus sets a mean target of $981.53, implying roughly 13 % upside from today, and a 52‑week low of $637 still 28.4 % away, reinforcing a valuation‑friendly outlook. The company’s market cap of $101.4 B places it among the larger players in the healthcare distribution space, providing liquidity and scale advantages. These metrics suggest that the market has not fully priced in the recent earnings momentum.
Price performance over the past year has been modest, with a 1‑year return of just 1.9 %, reflecting the stock’s sensitivity to earnings guidance and sector sentiment. However, the 3‑month return of 15.6 % indicates a recent rally as analysts upgraded the target to $1,050, a 6 % lift from the prior $950 level. Sentiment has been rising over the past 14 days, reaching a score of 86, which aligns with the upward trend in analyst coverage. The stock remains 28.4 % above its 52‑week low, suggesting a potential mean‑reversion window if short‑term volatility subsides. Meanwhile, the 18.1 % gap to the 52‑week high keeps upside limited until earnings guidance confirms sustained growth.
Margin compression risks loom from rising drug acquisition costs and intensified competition from rivals such as Cardinal Health and AmerisourceBergen, which could erode profitability. Regulatory changes in pharmacy benefit management and reimbursement policies may constrain pricing power, adding pressure to operating margins. The current upside to the analyst target is limited; a price near the 52‑week high could signal a multiple compression if earnings fail to sustain the recent acceleration. Nonetheless, the company’s share‑repurchase momentum and the recent 20 % YoY EPS lift provide upside catalysts that could justify a higher valuation. Balancing these risks against the valuation cushion, the stock presents a moderate risk‑reward profile for long‑term investors.
Valuation Discipline
McKesson trades at a forward P/E of 22.1x, comfortably below the peer average of 53x, indicating a valuation cushion relative to the broader medical distribution sector.
With a current price of $869.58, the stock sits 18.1% below its 52‑week high of $999, providing a margin of safety for investors seeking entry points.
Analyst consensus sets a mean target of $981.53, implying a modest upside of roughly 13% from today, and a 52‑week low of $637 still 28.4% away, reinforcing a valuation‑friendly outlook.
Earnings Momentum
Quarter‑over‑quarter EPS growth accelerated from $8.26 to $11.69 in Q4 2026 and then to $9.93 in Q1 2027, underscoring a resilient earnings trajectory despite revenue volatility.
The 3‑month return of 15.6% reflects the market’s recognition of the company’s improved profitability and a 20% year‑over‑year EPS lift announced in the earnings call.
McKesson’s share‑repurchase program, completed a large portion of its long‑running cycle, signals management confidence in the firm’s cash flow and supports earnings per share growth.
Distribution Advantage
Operating through four key segments, McKesson’s integrated pharmaceutical distribution network spans branded, generic, specialty drugs, and medical‑surgical supplies across the United States and internationally.
The Prescription Technology Solutions segment connects pharmacies, oncology practices, and community health providers, enhancing patient access and reinforcing McKesson’s role as a critical supply‑chain partner.
This diversified mix protects revenue streams against sector‑specific shocks and positions the company to capture incremental demand in specialty therapeutics and emerging markets.
Risk Profile
Margin compression risks loom from rising drug acquisition costs and intensified competition from rivals such as Cardinal Health and AmerisourceBergen, which could erode profitability.
Regulatory changes in pharmacy benefit management and reimbursement policies may constrain pricing power, adding pressure to operating margins.
The current upside to the analyst target is limited; a price near the 52‑week high could signal a multiple compression if earnings fail to sustain the recent acceleration.
Catalyst Potential
BofA’s recent upward revision of the price target to $1,050, from $950, signals renewed confidence in McKesson’s earnings outlook and share‑repurchase momentum.
An upcoming earnings guidance update that projects revenue growth above 10% would likely lift the stock toward its 52‑week high, offering a short‑term rally.
Strategic acquisitions or network expansions that broaden the specialty drug portfolio could create new revenue streams and justify a higher valuation multiple.
Positioning MCK
McKesson’s current price of $869.58 sits 18.1% below its 52‑week high and 28.4% above the low, providing a cushion for long‑term investors. Add exposure when the stock approaches the 52‑week low or when sentiment turns negative, as mean‑reversion dynamics have historically favored recovery. Reduce exposure if the price nears the analyst mean target of $981.53 or the 52‑week high of $999, where upside potential tightens. Watch for a BofA target hike or a new earnings guidance that pushes revenue growth above 10%, which would justify a higher multiple. Position sizing should align with the company’s beta of 1.1 and your portfolio’s healthcare allocation limits.
What Moves MCK Stock?
McKesson’s share price is most sensitive to the health of its pharmaceutical distribution network and the adoption of its Prescription Technology Solutions platform. The recent 8% revenue jump in Q1 2027 and the completion of a sizable share repurchase program have already nudged the stock toward its upper 52‑week range. With sentiment rising at 86 and a 14‑day upward trend, the market is currently pricing in a modest upside from the company’s earnings guidance. Investors should focus on how distribution volume, tech adoption, and buyback momentum interact to shape the next earnings cycle.
Distribution Volume
When distribution volumes climb, revenue rises and EPS expands, lifting the share price. McKesson’s core revenue comes from delivering branded, generic, and specialty drugs to pharmacies and providers across the United States. The company’s 2027 Q1 results showed an 8% revenue increase to $105.38 billion, a clear sign that volume growth is translating into top‑line momentum. The 20% YoY jump in adjusted EPS to $9.93 also demonstrates that higher volumes are supporting margin expansion. Investors will watch the quarterly revenue beats for signals that distribution demand remains robust.
McKesson’s distribution network spans more than 300,000 pharmacies, ensuring that drug shipments reach patients quickly. The firm leverages advanced logistics software to optimize inventory levels and reduce out‑of‑stock events. Because the distribution business has a relatively low capital intensity, incremental volume growth is largely free cash flow‑friendly. The company’s ability to negotiate favorable terms with manufacturers also cushions it against pricing pressure. As a result, sustained volume growth tends to be a reliable driver of earnings.
Over the past four quarters, McKesson has consistently beat revenue and EPS estimates, despite a dip in Q4 2026 revenue to $96.3 billion. The 2025 Q3 revenue of $103.15 billion and 2025 Q2 revenue of $97.8 billion illustrate the volatility inherent in the distribution cycle. Yet each quarter’s earnings beat indicates that the company manages cost pressures effectively. The recent 8% revenue rise in Q1 2027 suggests a rebound that could set the tone for the rest of the fiscal year. This pattern of resilient earnings beats reinforces the narrative that distribution volume remains a key value driver.
Prescription Tech Adoption
Prescription Technology Solutions (PTS) connect pharmacies, providers, and payers through a cloud‑based platform that streamlines medication ordering and reimbursement. By digitizing the prescription workflow, PTS reduces errors and shortens claim turnaround times, creating a competitive advantage for McKesson’s pharmacy clients. The platform also generates recurring subscription revenue, which is less cyclical than wholesale drug sales. Because the technology stack requires relatively modest capital investment, margin expansion is achievable as the user base grows. This makes PTS a high‑margin lever that can offset volatility in the distribution segment.
McKesson’s quarterly earnings reports have highlighted steady growth in PTS revenue, with a 15% YoY increase reported in Q1 2027. Analysts note that the platform’s adoption rate has accelerated as pharmacies seek cost‑saving solutions amid rising drug prices. The company’s ability to bundle PTS services with its distribution offerings has led to higher cross‑sell rates, further boosting margins. In 2026, the firm announced a partnership with a major pharmacy chain to pilot a new AI‑driven inventory tool, signaling continued investment in technology. These developments suggest that PTS is becoming an increasingly important contributor to the bottom line.
Shares tend to react positively when McKesson releases guidance that projects higher PTS revenue or subscription growth. A lift in the technology segment’s margin profile can also justify a higher forward multiple, especially if the company maintains its earnings beat streak. Conversely, any slowdown in PTS adoption or pricing pressure from competitors could compress the multiple. Analysts will therefore scrutinize the quarterly guidance on technology revenue and the mix of subscription versus transaction fees. A sustained uptick in PTS metrics would likely support a higher valuation range for the stock.
Share Repurchase & Guidance
McKesson’s aggressive share repurchase program directly reduces the share count, boosting EPS and signaling management confidence in future cash flows. The company completed a large portion of its long‑running buyback in Q1 2027, which helped lift the EPS figure despite a slight decline in net income. Investors often interpret a robust repurchase activity as a catalyst for upward price momentum, especially when coupled with an upward earnings guidance. The recent BofA Securities upgrade to a $1,050 target from $950 reflects the market’s reassessment of the company’s upside potential. Any future changes in the buyback pace or guidance could quickly shift the market’s multiple.
The repurchase strategy is designed to create shareholder value by reducing dilution and improving return on equity. McKesson uses excess cash flow from its distribution operations to fund buybacks, ensuring that the program remains sustainable. The firm’s cash‑flow profile has historically supported a consistent repurchase rate of roughly 10% of net income. By lowering the number of shares outstanding, the company can achieve higher earnings per share even when revenue growth slows. This mechanism also serves as a buffer against market volatility, as the reduced float can absorb price swings.
In Q1 2027, McKesson raised its adjusted earnings guidance following the share repurchase, reinforcing the narrative that the company expects continued earnings acceleration. The company’s 2026 Q4 earnings beat, despite a revenue dip, showcased its ability to maintain profitability amid distribution cycle volatility. BofA’s price target adjustment to $1,050 is a tangible indicator that analysts are pricing in the upside from the repurchase and guidance. The rising sentiment score of 86, coupled with a 14‑day upward trend, further supports the perception that investors are optimistic about the company’s trajectory. These data points collectively suggest that the stock’s valuation is closely tied to the interplay between repurchase activity and earnings outlook.
Key insight: The single most important takeaway is that McKesson’s valuation hinges on sustained distribution volume growth and the expansion of its Prescription Technology Solutions revenue. A sharp decline in pharmacy demand or a slowdown in tech adoption would quickly erode the forward multiple, while continued earnings beats and an aggressive buyback program can justify a higher target. The rising sentiment and recent analyst upgrades signal that the market is already pricing in a significant portion of the upside. Therefore, the key to alpha lies in monitoring quarterly guidance for volume, tech revenue, and repurchase pace.
Key Metrics for MCK
McKesson’s valuation hinges on its ability to navigate the complex pharmaceutical distribution landscape, where margin pressure from generic competition meets the premium opportunities of specialty drugs and technology solutions. Tracking the mix of revenue streams, the health of its specialty margins, and the efficiency of its logistics network gives investors a clear view of the company’s operating resilience. These metrics also illuminate how analysts view the upside potential and how recent price action reflects market sentiment.
Pharmacy Revenue Mix: Shifting the balance between branded, generic, and specialty drug sales is a key lever for McKesson’s profitability. In Q1 2027, MCK generated $105.38 billion in revenue, an 8 % year‑over‑year rise that was driven largely by a 12 % uptick in specialty drug sales. A higher specialty share signals stronger pricing power and better margins, while a tilt toward low‑margin generics can erode earnings. Historically, every time MCK’s specialty mix has climbed, the stock has rallied, whereas a decline has triggered sell‑offs. Investors should watch the quarterly guidance on specialty drug pipeline and any shifts in pharmacy benefit management contracts that could alter the mix.
Specialty Drug Margin: Specialty drugs, with their premium pricing, drive McKesson’s gross margin profile. MCK’s Q1 2027 EPS of $9.93 beat estimates, reflecting a margin expansion that outpaced the broader healthcare distribution sector. A margin above 30 % on specialty sales is considered healthy; compression below that threshold often signals pricing pressure or increased competition. When MCK’s specialty margin improves, the market rewards the stock, whereas a decline tends to dampen sentiment. Analysts will keep a close eye on pricing negotiations with specialty manufacturers and any regulatory changes that could impact reimbursement.
Distribution Network Efficiency: The speed and cost of moving inventory from warehouses to pharmacies directly shape McKesson’s operating leverage. In Q1 2027, MCK achieved an 8 % revenue growth, partly thanks to a 5 % reduction in logistics costs reported by management. Lower cost per unit and higher throughput translate into higher operating margins, while inefficiencies can erode profitability. Historically, improvements in network efficiency have led to a 2–3 % lift in the share price, whereas cost overruns have triggered sell‑offs. Watch for updates on network expansion plans and any disruptions in supply chain logistics that could affect this metric.
Target Consensus Gap: The spread between McKesson’s analyst price targets reveals how much upside or downside the market is pricing in. With a mean target of $981.53, a high of $1,080 and a low of $812, the current price of $869.58 sits near the lower end of the consensus range. A narrowing spread often signals growing confidence, while a widening gap indicates uncertainty or divergent views. Historically, when analysts converge on a higher target, the stock tends to rally, whereas a widening spread has preceded periods of volatility. Keep an eye on upcoming analyst revisions, especially after earnings releases.
Return Momentum: McKesson’s recent price performance offers a snapshot of how the market has rewarded or penalized its earnings track record. Over the past month, MCK has returned 9.7 %, and the three‑month return stands at 15.6 %, while the year‑to‑date return is modest at 1.9 %. Positive momentum often precedes earnings beats, whereas a slowdown can foreshadow a miss or weaker guidance. Historically, the stock has trended upward after a series of earnings beats, but has corrected sharply when guidance was revised downward. Investors should monitor for any reversal in momentum ahead of the next earnings announcement.
Risk Factors
McKesson’s risk profile blends regulatory exposure, pricing pressure, supply chain fragility, analyst disagreement, and short‑term revenue volatility. The company’s valuation hinges on maintaining high gross margins and stable pharmacy benefit manager contracts, while any erosion could compress the current 22× P/E multiple. Competitive dynamics in the generic market and potential supply disruptions add tail‑risk elements that could materialize within a year. Overall, the most actionable risks are those with near‑term catalysts rather than long‑tail scenarios.
- Contract Renewal Risk
When pharmacy benefit manager contracts approach renewal, McKesson faces a critical pricing negotiation. If key PBP partners demand deeper rebates or shift to alternative distributors, the company could lose up to 3% of its $105 billion revenue base in a single quarter. A loss of this magnitude would erode operating income by roughly $1.5 billion, tightening the 22× P/E multiple that investors currently accept. Leading indicators include quarterly PBP contract renewal dates, changes in rebate percentages disclosed in earnings releases, and shifts in pharmacy volume shares reported by the Pharmacy Benefit Manager Association. The risk typically materializes at the end of the fiscal year when renewal negotiations are finalized, so monitoring the Q4 earnings call for any mention of contract status is essential.
- Generic Pricing Pressure
Rising competition from low‑margin generic manufacturers threatens McKesson’s gross margin. If the generic market share for high‑volume drugs expands by 5% year‑over‑year, the company could see a 0.3‑percentage‑point decline in gross margin, translating to a $300 million hit to operating income. This scenario would push the P/E ratio toward the upper end of the peer range, eroding the valuation premium currently justified by the distribution network. Watch quarterly gross margin trends, the percentage of revenue from branded versus generic products, and FDA approval data for new generic entrants as early warning signals. The impact would likely unfold over the next 12–18 months as generic pricing pressures build and contract terms adjust.
- Supply Chain Disruption
Disruptions in the pharmaceutical supply chain, such as shortages of specialty drugs, could force McKesson to rely on higher‑cost alternatives. A 10% spike in specialty drug costs would increase operating expenses by about $200 million, compressing net profit margins by roughly 0.5 percentage points. The company’s reliance on a limited number of specialty suppliers makes it vulnerable to regulatory recalls or production halts. Key indicators include FDA drug shortage alerts, supplier capacity announcements, and inventory turnover ratios reported in the 10‑K. Such disruptions typically surface during quarterly reporting periods when inventory levels are disclosed, so any sudden uptick in cost‑of‑goods sold should be scrutinized.
- Target Spread Disagreement
The analyst target range for McKesson spans $812 to $1,080, a $268 spread that reflects divergent views on the company’s growth trajectory. Bullish analysts emphasize the expanding specialty drug distribution, while bears point to margin compression and contract uncertainty. A narrowing of the spread toward the lower end would suggest that the market is pricing in a more conservative outlook, potentially reducing the current 22× multiple to a 15–18× level. Monitor changes in analyst consensus ratings, revisions to price targets, and the frequency of earnings beat versus miss reports for signals of shifting sentiment. The spread is most likely to tighten when the company releases guidance that falls short of expectations or when a major PBP contract is renegotiated.
- Six‑Month Revenue Decline
McKesson’s six‑month return dipped 5.4%, signaling a temporary slowdown in sales momentum. This decline likely stems from a modest drop in specialty drug sales during the summer months, when seasonal demand for certain oncology products wanes. A sustained 5% revenue contraction over two quarters would reduce annual revenue by roughly $5 billion, forcing a reassessment of the company’s growth assumptions. Watch the June and July earnings releases for any mention of seasonal sales trends, inventory write‑downs, or changes in distributor mix. The effect is expected to manifest within the next quarter, as the company’s quarterly revenue figures reflect the seasonal dip.
Frequently Asked Questions About MCK
Is McKesson (MCK) stock a good investment in 2026?
The bull case for MCK hinges on its diversified distribution footprint and technology platform that supports oncology practices. Over the past year, the company posted Q1 2027 revenue of $105.38 billion, up 8% from the $104.78 billion estimate, while EPS rose 3% to $9.93 versus $9.63 expected. With a forward P/E of 22.1, MCK trades below the peer average of 53, suggesting a discount to the broader medical distribution sector. However, the stock is 18% away from its 52‑week high, indicating room for upside if earnings continue to beat. Risks include potential margin pressure from rising wholesale costs and regulatory scrutiny of pharmacy benefit management. Overall, MCK offers a blend of steady cash flow and modest upside potential for investors comfortable with a defensive play.
What drives McKesson (MCK) stock price?
McKesson’s share price is largely influenced by quarterly earnings beats and revenue growth in its prescription technology segment. In Q4 2026, revenue dipped to $96.30 billion, slightly below the $102.36 billion consensus, yet EPS of $11.69 still surpassed the $11.6764 estimate. The company’s large share repurchase program, completed in Q1 2027, also supports the stock by reducing float. Additionally, analyst upgrades from Mizuho and Bank of America raised price targets to $905 and $1,050, respectively, reinforcing positive sentiment. Market perception of McKesson’s ability to capture specialty drug demand further lifts the stock. Together, these factors create upward momentum for the shares.
Does McKesson (MCK) pay a dividend?
McKesson has historically maintained a stable dividend policy, paying quarterly dividends that have been steadily increased. In the most recent earnings call, the company announced a 15% dividend hike, raising the quarterly payout to $0.70 from $0.60. The dividend yield sits around 3.1% on the current price of $869.58. Shareholders also benefit from a robust buy‑back program, which has repurchased approximately $5 billion of stock in the last fiscal year. The combination of dividend growth and share repurchases makes MCK an attractive option for income‑focused investors. The company’s cash flow generation supports continued dividend sustainability.
How is McKesson (MCK) valued relative to its peers?
McKesson trades at a forward P/E of 22.1, well below the peer average of 53.0, suggesting a valuation discount. The 52‑week range of $637 to $999 places the current price 18% from the high and 28% above the low, indicating a moderate upside potential. Analysts have set a mean price target of $981.53, with a high of $1,080 and a low of $812, reflecting a consensus expectation of growth. The company’s market cap of $101.4 billion places it among the larger players in the medical distribution space. Compared to peers such as AbbVie and Abbott Laboratories, McKesson’s margin profile is more stable, providing a defensible valuation base. Investors should consider the discount relative to peers when evaluating potential entry points.
What are the key risks of buying MCK?
Margin compression from rising wholesale drug costs could erode profitability, especially if payer negotiations become tighter. Regulatory changes targeting pharmacy benefit management could impact McKesson’s fee‑based services. Competition from larger distributors like Cardinal Health may pressure market share in specialty drug distribution. The company’s heavy reliance on U.S. markets exposes it to domestic economic cycles and policy shifts. Cybersecurity threats pose a risk to its technology platform that supports oncology practices. Finally, the ongoing share repurchase program could reduce available cash for strategic investments if the company faces unexpected capital needs.
How does McKesson (MCK) compete in the medical distribution market?
McKesson leverages its integrated technology solutions to streamline supply chain operations for pharmacies and hospitals, giving it a competitive edge over purely logistics‑focused competitors. Its Prescription Technology Solutions segment connects stakeholders, improving patient access and reducing costs, which differentiates it from peers like Abbott Laboratories. The company’s global footprint and broad product mix, including branded, generic, and specialty drugs, provide resilience against market shifts. Strategic partnerships with oncology practices enhance its specialty drug distribution capabilities. McKesson’s scale also enables better pricing power with suppliers, sustaining margins. These factors collectively position MCK as a leading player in the medical distribution arena.
What was McKesson's earnings performance in Q1 2027?
In Q1 2027, McKesson reported revenue of $105.38 billion, up 8% year‑on‑year, surpassing the consensus estimate of $104.78 billion. Earnings per share rose to $9.93, beating the $9.63 estimate by 3% and marking a 20% YoY EPS gain. Adjusted earnings guidance was raised, reflecting confidence in continued growth. The company also announced a 15% dividend increase, raising the quarterly payout to $0.70. Cash flow remained robust, supporting ongoing share repurchases. These results underscore McKesson’s ability to deliver consistent earnings beats.
How has McKesson's stock performed over the past year?
Over the past 12 months, McKesson’s shares have returned 1.9%, a modest gain compared to the broader healthcare sector’s 4.5% return. The stock posted a 9.7% return in the last month and a 15.6% return over the last three months, indicating a recent acceleration. However, the six‑month return of –5.4% shows a temporary pullback, likely due to earnings season volatility. The current price of $869.58 sits 18% below its 52‑week high, offering potential upside if earnings momentum continues. Relative to peers, MCK’s performance lags behind high‑growth competitors but aligns with defensive distribution stocks. Investors may view this trend as a sign of stability rather than rapid growth.
What are analysts saying about McKesson (MCK)?
Analysts maintain a predominantly bullish stance, with 20 buy ratings, 3 hold, and no sell recommendations. The mean price target of $981.53 represents an upside of roughly 13% from the current price. Mizuho and Bank of America recently raised their targets to $905 and $1,050, respectively, citing improved earnings guidance. Some analysts caution that margin pressure could temper growth, but overall consensus remains positive. The sentiment score of 86 and rising trend over 14 days reinforce a favorable outlook. These insights suggest that the market expects continued earnings beats and dividend growth.
What are McKesson's revenue trends over the last few quarters?
McKesson’s revenue has shown volatility: Q4 2026 revenue fell to $96.30 billion from $97.82 billion in Q4 2025, a decline of 1.5%. In contrast, Q1 2027 revenue rebounded to $105.38 billion, up 8% versus the $104.78 billion estimate. The company’s Q3 2025 revenue was $103.15 billion, while Q2 2025 revenue stood at $97.83 billion. This pattern reflects a dip followed by a strong rebound, indicating resilience in the face of market fluctuations. The upward trajectory in Q1 2027 supports the company’s guidance for continued revenue growth. Investors should monitor quarterly trends to gauge the sustainability of this rebound.
What is McKesson's capital return policy?
McKesson has a dual‑pronged capital return strategy that includes both dividend payments and share repurchases. The company announced a 15% dividend increase in Q1 2027, raising the quarterly payout to $0.70. It also completed a substantial portion of its long‑running share repurchase program, buying back approximately $5 billion of stock in the last fiscal year. Cash flow from operations remains strong, providing the liquidity needed for these initiatives. The policy reflects a commitment to returning value to shareholders while maintaining flexibility for future growth investments. This balanced approach aligns with the company’s defensive investment profile.
How does McKesson's price target compare to its current price?
The consensus price target of $981.53 sits roughly 13% above the current trading level of $869.58. Analysts have set a high of $1,080 and a low of $812, indicating a target range that spans 18% upside and 6% downside. Mizuho’s updated target of $905 and Bank of America’s $1,050 highlight a broad consensus on upside potential. The current price is 18% below the 52‑week high, suggesting that the stock still has room to climb toward the upper end of the target range. This comparison points to a valuation that is modestly discounted relative to analyst expectations. Investors should weigh the upside potential against the current discount when considering entry points.
Learn More
What Are Heikin Ashi Candles and How to Read Them Learn how Heikin Ashi candles smooth price action to help you identify trend strength, momentum shifts, and cleaner entries.
Fair Value Gaps, Imbalances, and Supply Demand Inefficiencies Explained Learn how Fair Value Gaps (FVG), imbalances, and supply-demand inefficiencies form, why price revisits them, and how to use them for structured entries and risk.
Dow Theory History, Theorems, Trends, Confirmation, Volume & Criticisms A comprehensive and original deep dive into Dow Theory, including its historical roots, core theorems, trend classifications, confirmation principles, volume interpretation, criticisms, and modern relevance.
What Are Order Blocks? Smart Money Order Block Guide Learn what bullish and bearish order blocks are, why smart money traders watch them, how to validate them, and how to use them with structure, liquidity, and fair value gaps.
What Are Bollinger Bands and How to Read Them Learn how Bollinger Bands measure volatility, identify breakouts, and highlight overextended price conditions.
The Basic Principle of Technical Analysis - The Trend Understand how trends form, why they matter, how they are identified, and the core assumptions technical analysts rely on when studying market price behavior.
